Skip to main content

Dr. Neil Kramer, MD

Rheumatology (Rheumatology Physician)

33 Overlook Rd, Suite L01
Summit, NJ 07901

Who else practices at this address →

Union County includes primary care (24% of residents) and mental health (5% of residents) shortage areas. About shortage areas

Call (908) 598-7940

  • Medicare participating

At a glance

Years since graduation
52
In the NPI registry since
2006
Medicare patients seen, 2024
120

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 1974Medical school: Perelman School of Med at the University of Pennsylvania
  • 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Rheumatology Physician primary
    NJ license 25MA03712500

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Rheumatology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
120
Services billed
9,944
Patients’ average age
76
Most frequent Medicare services, 2023
ServiceTimesPatients
Injection, denosumab, 1 mg1,26012
Established patient office or other outpatient visit, 30-39 minutes21986
Injection of drug or substance under skin or into muscle11522
Injection, triamcinolone acetonide, not otherwise specified, 10 mg3913

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 12 companies reported 66 payments worth $1,129 in total to this clinician.

By type
Food and Beverage$1,129

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in New Jersey →

Industry-funded research

Named as a principal investigator on 9 industry-funded studies in 2025, from 4 companies. The companies reported $1,113,703 in research payments for these studies, mostly to the institutions running them.

  • A Phase 1, Multicenter, Open-Label Study Of CC-97540 (BMS-986353), CD19-Targeted Nex-T Chimeric Antigen Receptor (CAR) T Cells, in Participants with Severe, Refractory Autoimmune Diseases: Systemic Lupus Erythematosus…
    Celgene Corporation
  • A Phase 1, Multicenter, Open-Label Study Of CC-97540 (BMS-986353), CD19-Targeted Nex-T Chimeric Antigen Receptor (CAR) T Cells, in Participants with Severe, Refractory Autoimmune Diseases: Systemic Lupus Erythematosus…
    E.r. Squibb & Sons, L.l.c.
  • A Phase 2, Multicenter, Open-Label Study Of CC-97540 (BMS-986353), CD19-Targeted NEXT CAR T Cells, in Participants with Active SLE (Including Lupus Nephritis) with Inadequate Response to Glucocorticoids and at Least 2…
    E.r. Squibb & Sons, L.l.c.
  • A Phase 2, Multicenter, Open-Label Study Of CC-97540 (BMS-986353), CD19-Targeted NEXT CAR T Cells, in Participants with Active SLE (Including Lupus Nephritis) with Inadequate Response to Glucocorticoids and at Least 2…
    Celgene Corporation
  • Multicenter Randomized Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Anifrolumab in Adult Patients with Active Proliferative Lupus Nephritis
    AstraZeneca Pharmaceuticals LP
  • A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)
    E.r. Squibb & Sons, L.l.c. · Active, not recruiting · NCT07015983
  • A Pregnancy and Newborn Safety Monitoring Study to Evaluate Outcomes Following Maternal Exposure to CD19Targeted NEXT CAR TCell Therapy (BMS986353)
    E.r. Squibb & Sons, L.l.c.
  • A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) (POETYK SLE-1)
    E.r. Squibb & Sons, L.l.c.
  • LUPKYNIS Registry Study
    Aurinia Pharma U.S., Inc.

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Rheumatology clinicians in Summit

Sources

NPI registry (CMS NPPES, November 2026; record last updated February 8, 2016), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1306808746. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.